APEIRON’s product pipeline includes five immune-oncology (IO) product candidates in clinical and discovery stages, and one marketed product that was licensed to a partner: the Cbl-b projects (APN401, APN431), the GD2 programs (APN311, APN301) and the novel IO discovery projects (APN411, APN421). Our non-IO product APN01, a recombinant enzyme of the Renin Angiotensin System, was out-licensed to GlaxoSmithKline which further validates APEIRON’s robust pipeline.
APN311 is a therapeutic antibody to treat pediatric patients with neuroblastoma, exclusively outlicensed to and marketed by EUSA Pharma as Qarziba®.
|Novel IO Targets
APEIRON`s novel immune oncology projects are directed against novel undisclosed targets and are being developed to treat tumors with substantial unmet medical need.
APN01 is a recombinant human Angiotensin Converting Enzyme 2 (rhACE2). This program was out-licensed to GlaxoSmithKline (GSK), which is currently conducting clinical studies in ALI (Acute Lung Injury) and PAH (Pulmonal arterial hypertension).